Objectives
The Proteomics Unit is specialized in conducting proteomic tests and analyses for R&D in the areas of cancer and infectious disease research.
Emphasizing large-scale studies, the unit explores the structures and functions of proteins in depth.
The Unit proudly provides accredited diagnostic tests for protein detection, analysis, and synthesis , ensuring the highest quality of service.
Areas of impact and applications in the field
The discovery of proteomic (proteome) biomarkers aids in early tumor diagnosis, prognosis, and treatment. Proteins found in the blood that have been produced from cells and surrounding tissues contain critical biological information that has the potential to revolutionize early diagnostic, prognostic, therapeutic, and even preventative decisions in medicine.
The Proteomics Unit of AnkaTheraHub is also crucial in infectious diseases, particularly emerging and re-emerging RNA viral infections. Furthermore, the relapse threatens the pre-antibiotic era with the increasing prevalence of microorganisms with multiple resistance to antibiotics or other agents,. Thus, the search for new options for effective control of infectious diseases is becoming increasingly important. With the aid of proteomics, the function of pathogens and hosts can now be considered globally, with the genome sequences as the basis for the monitoring of proteins, their modifications, and interactions. Applying bioinformatics and the new technical achievements mean it is increasingly possible to characterize complex mixtures and thus open to new therapeutic possibilities.
Areas of impact and applications in the field
Regarding cancer research, synthetic biology seeks to re-design biological systems to perform novel functions in a predictable way. Recent advances in bacterial and mammalian cell engineering include the development of cells that function in biological samples or within the body as minimally invasive diagnostics or theranostics for the real-time regulation of complex pathological conditions. Ex-vivo and in-vivo cell-based biosensors and therapeutics have been developed to target a wide range of diseases including cancer.
A major milestone in the field of theranostic cell engineering was the 2017 FDA approval of tisagenlecleucel, the first gene therapy to be approved in the USA. Considering the above, this facility will work on preclinical applications of mammalian sensing and drug delivery platforms as well as underlying biological designs that could lead to new classes of cell diagnostics and therapeutics.
In the context of infectious diseases, there is a growing need for novel, specific, sensitive, and effective diagnostic and treatment procedures. Synthetic systems and devices are evolving into strong tools for treating human infections. The advancement of synthetic biology provides platforms for detecting and preventing infectious diseases that are efficient, accurate, and cost-effective.
Services
List of Equipments
